Kynam Capital Management, LP Protagonist Therapeutics, Inc Transaction History
Kynam Capital Management, LP
- $1.58 Billion
- Q4 2024
A detailed history of Kynam Capital Management, LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Kynam Capital Management, LP holds 390,792 shares of PTGX stock, worth $20.7 Million. This represents 0.96% of its overall portfolio holdings.
Number of Shares
390,792
Previous 456,369
14.37%
Holding current value
$20.7 Million
Previous $20.5 Million
26.45%
% of portfolio
0.96%
Previous 1.68%
Shares
10 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$315 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$305 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$292 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$224 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$177 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.6B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...